PubMed Health⌕ Search

Biomedical subjects

F Sun

Publications and source records attributed to F Sun.

154 records · Page 9Linked to original sources
PubMed1979

9,11-Iminoepoxyprosta-5,13-dienoic acid is a selective thromboxane A2 synthetase inhibitor.

9,11-Iminoepoxyprosta-5,13-dienoic acid inhibits the thromboxane A2 synthetase in platelet and lung microsomal enzyme preparations and in intact platelets. It does not inhibit the protaglandin I2 synthetase in aorta or lung microsomes and intact Balb 3T3 fibroblasts. In lung microsomes, which contain both enzymes, 9,11-iminoepoxyprosta-5,13-dienoic acid inhibits only thromboxane A2 formation and augments prostaglandin I2 formation. This inhibitor is more selective than other reported prostaglandin endoperoxide analogs which inhibit the platelet thromboxane synthetase.

Animals↗
PubMedDate not supplied

Isolation of <Glu-Asn-Phe-His-Leu-Arg-Pro-NH2 (Antho-RPamide II), a novel, biologically active neuropeptide from sea anemones.

Using a radioimmunoassay against the C-terminal sequence Arg-Pro-NH2 (RPamide) we have isolated the neuropeptide <Glu-Asn-Phe-His-Leu-Arg-Pro-NH2 (Antho-RPamide II) from extracts of the sea anemone Anthopleura elegantissima. Addition of low concentrations of Antho-RPamide II to a tentacle preparation of sea anemones inhibited the spontaneous, rhythmic contractions, suggesting that the peptide is a neurotransmitter or neuromodulator.

Amino Acid Sequence↗
PubMedDate not supplied

Chemical characterization and toxicity of dihydro derivatives of nodularin and microcystin-LR, potent cyanobacterial cyclic peptide hepatotoxins.

Dihydro derivatives of nodularin (1) and microcystin-LR (4), potent cyclic peptide hepatotoxins isolated from Nodularia spumigena and Microcystis aeruginosa, respectively, were prepared by sodium borohydride reduction of the dehydroamino acid residues. The two stereoisomers of both dihydronodularin (2 and 3) and dihydromicrocystin-LR (5 and 6), isolated by reversed-phase HPLC, showed similar toxicity to each other [ip in mice, LD50 = 150 (2), 150 (3), 85 (5), and 100 (6) micrograms/kg]. The stereochemistries of the reduced amino acids obtained by acid hydrolysis of dihydronodularin and dihydromicrocystin-LR [respectively, alpha-(methylamino)butyric acid and N-methylalanine] were determined by GC on a permethylated beta-cyclodextrin capillary column as their trifluoroacetyl methyl ester derivatives. Authentic L- and DL-N-methylamino acids were prepared to compare directly with the natural amino acids. Deuterated derivatives were also prepared using sodium borodeuteride (98 atom % D), and the location (beta) and percentage (78-84%) of the deuterium incorporation were determined.

Animals↗
PubMedDate not supplied

Estimation of the mutation rate during error-prone polymerase chain reaction.

Error-prone polymerase chain reaction (PCR) is widely used to introduce point mutations during in vitro evolution experiments. Accurate estimation of the mutation rate during error-prone PCR is important in studying the diversity of error-prone PCR product. Although many methods for estimating the mutation rate during PCR are available, all the existing methods depend on the assumption that the mutation rate is low and mutations occur at different places whenever they occur. The available methods may not be applicable to estimate the mutation rate during error-prone PCR. We develop a mathematical model for error-prone PCR and present methods to estimate the mutation rate during error-prone PCR without assuming low mutation rate. We also develop a computer program to simulate error-prone PCR. Using the program, we compare the newly developed methods with two other methods. We show that when the mutation rate is relatively low (< 10(-3) per base per PCR cycle), the newly developed methods give roughly the same results as previous methods. When the mutation rate is relatively high (> 5 x 10(-3) per base per PCR cycle, the mutation rate for most error-prone PCR experiments), the previous methods underestimate the mutation rate and the newly developed methods approximate the true mutation rate.

Biometry↗
PubMedDate not supplied

On the use of population-based registries in the clinical validation of genetic tests for disease susceptibility.

PURPOSE: Many new genetic tests for susceptibility to adult-onset diseases are developed on the basis of selected and high-risk groups. Before such tests can be used in medical practice, however, epidemiologic studies must be conducted to evaluate their clinical sensitivity, specificity, and positive predictive value in the general population. For many common adult-onset diseases, this process may take decades of follow-up. METHOD: We illustrate how clinical validation of new predictive genetic tests can be done retrospectively using case-control studies that are derived from population-based registries of diseases. We use the examples of birth defects and cancer registries to illustrate a hypothetical process by which such tests can be clinically validated. RESULTS: We demonstrate how such epidemiologic studies can be successfully used to derive measures of a test's sensitivity, specificity, positive predictive value, negative predictive value, and of the population attributable fraction of disease due to the disease-susceptibility genes. Under certain assumptions, data derived from population-based case-control studies provide adequate estimates of lifetime risks for disease (penetrance) among people with specified genotypes. CONCLUSIONS: With adequate protections of human subjects, studies involving population-based registries of disease will increasingly become valuable in validating the numerous genetic tests that will emerge from advances in human genetic research and the Human Genome Project.

Adult↗